Brief: Immunocore Says UK, Australia And Canada Approve Kimmtrak For Treatment Of Unresectable Or Metastatic Uveal Melanoma
08/06/2022 13:44
June 8 (Reuters) - Immunocore Holdings PLC IMCR.O :
* THE UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
(MHRA), AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION (TGA) AND
HEALTH CANADA APPROVE KIMMTRAK® (TEBENTAFUSP) FOR THE TREATMENT
OF UNRESECTABLE OR METASTATIC UVEAL MELANOMA
Source text for Eikon: ID:nGNXcbNQXC
Further company coverage: IMCR.O
((Reuters.Briefs@thomsonreuters.com;))